Last reviewed · How we verify

or Metformin HCl alone — Competitive Intelligence Brief

or Metformin HCl alone (or Metformin HCl alone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

or Metformin HCl alone (or Metformin HCl alone) — Bristol-Myers Squibb. Metformin HCl reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in patients with type 2 diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
or Metformin HCl alone TARGET or Metformin HCl alone Bristol-Myers Squibb marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
Metformin up-titration Metformin up-titration Research Clinical Centre of the Russian Railways, JSC marketed Biguanide AMP-activated protein kinase (AMPK), mitochondrial respiratory chain complex I
semaglutide combined with metformin semaglutide combined with metformin The First Affiliated Hospital of Xiamen University marketed GLP-1 receptor agonist combined with biguanide GLP-1R; AMPK pathway
metformin\pioglitazone\exenatide metformin\pioglitazone\exenatide The University of Texas Health Science Center at San Antonio marketed Combination antidiabetic agent (biguanide + thiazolidinedione + GLP-1 receptor agonist) Multiple: AMPK pathway (metformin), PPAR-γ (pioglitazone), GLP-1 receptor (exenatide)
metformin or sulfonylurea metformin or sulfonylurea Dr. Milan Gupta marketed Antidiabetic agents (biguanide and sulfonylurea) Metformin: AMP-activated protein kinase (AMPK) pathway; Sulfonylureas: ATP-sensitive potassium channel (KATP)
Metformin and insulin Metformin and insulin Takeda marketed Antidiabetic combination (biguanide + insulin) Metformin: AMP-activated protein kinase (AMPK) pathway; Insulin: insulin receptor
MET + Vildagliptin Group MET + Vildagliptin Group Hospital de Clinicas de Porto Alegre marketed Combination antidiabetic agent (biguanide + DPP-4 inhibitor) Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

  1. AstraZeneca · 4 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. University of Texas Southwestern Medical Center · 2 drugs in this class
  4. Mount Sinai Hospital, Canada · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Eli Lilly and Company · 2 drugs in this class
  7. University Magna Graecia · 2 drugs in this class
  8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
  10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). or Metformin HCl alone — Competitive Intelligence Brief. https://druglandscape.com/ci/or-metformin-hcl-alone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: